%

Right
Targets
Vectors
Patients
Time
We use cookies to improve your experience on our website. You can accept all the cookies, reject them or select your cookie preferences by clicking the corresponding buttons. For more information, please see our cookie policy.

Empowering the Future

Positioned to deliver revolutionary cancer vaccines

OUR MISSION

To Cure Cancer:
Right Targets, Right Vectors,
Right Patients, Right Time

Blue small t-cellBlue small t-cell
Using our Infinitopes Precision Immunomics™ pipeline, we can reliably identify highly-expressed and immunogenic tumour antigens presented by cancer cells.

We achieve unparalleled sensitivity by coupling bleeding-edge laboratory, computation, and ML workflows. Our discovery platform is validated in preclinical models and shows superior tumour protection compared to known antigens.
Our vector platform is built on nearly a decade of immunology research and is carefully designed to induce industry-leading T cell immunity, both in magnitude and durability.
Leveraging the expertise of our team who have led, designed or support >70 Phase I-III clinical trials in oncology, we are initiating our FIH trial in 2024 - only 3 years after company inception.

Our approach to translation aims to optimise the window of effect and cancer types for patients to respond to vaccine treatment.

We are global in our vision to change cancer care, so that there is no ‘singular’ right patient or demographic for an effective vaccine.
Initiating treatment at the earliest stage in the patient's journey is critical. Our approach ensures swift vaccine administration, offering treatment when patients are most robust, and their prognosis is more favourable.

Our strategy is integrated with conventional care, drawing from our collective expertise in immuno-oncology and vaccinology to enhance standard treatment protocols.

OUR MISSION

To Cure Cancer:
Right Targets, Right Vectors, Right Patients, Right Time

Right Time

Initiating treatment at the earliest stage in the patient's journey is critical. Our approach ensures swift vaccine administration, offering treatment when patients are most robust, and their prognosis is more favourable.

Our strategy is integrated with conventional care, drawing from our collective expertise in immuno-oncology and vaccinology to enhance standard treatment protocols.

Right Patients

Leveraging the expertise of our team who have led, designed or support >70 Phase I-III clinical trials in oncology, we are initiating our FIH trial in 2024 - only 3 years after company inception.

Our approach to translation aims to optimise the window of effect and cancer types for patients to respond to vaccine treatment.

We are global in our vision to change cancer care, so that there is no ‘singular’ right patient or demographic for an effective vaccine.

Right Vectors

Our vector platform is built on nearly a decade of immunology research and is carefully designed to induce industry-leading T cell immunity, both in magnitude and durability.

Right Targets

Using our Infinitopes Precision Immunomics™ pipeline, we can reliably identify highly-expressed and immunogenic tumour antigens presented by cancer cells.

We achieve unparalleled sensitivity by coupling bleeding-edge laboratory, computation, and ML workflows. Our discovery platform is validated in preclinical models and shows superior tumour protection compared to known antigens.

Previous
Next
TIMELINE

Embarking on a journey from innovation to impact

Our journey to PhaseI/IIa clinical trials is being accelerated to start by end of 2024

2017-2020:

CRUK Cancer Immunology Project Award

2019-2021:

Emerson Fellowship Award - Optimisation of Immunotherapy

2019-2023:

CRUK Cancer Vaccines Fellowship Award

2021:

Infinitopes spun out of Oxford University

March 2022:

First Lab opens at Oxford's BioEscalator

August 2022:

Innovate UK Biomedical Catalyst Winner - Funds our first human trial

September 2022:

Awarded Innovative Licensing Access Pathway (ILAP) innovation passport

November 2022:

Granted Worldwide Exclusive Licence to CRUK Vector & Epitope Technologies

August 2023:

Inaugural Immuno-Oncology Summer School

September 2023:

Innovate UK Future Economy Investor Partnership Winner - To target five more cancers

December 2023:

Seed Round Closed (x3 oversubscribed)

April 2024:

Installation of next generation LC-MS/MS

Spring 2024:

GMP vaccine biomanufacturing complete (on schedule)

Summer 2024:

Phase I/IIa clinical trial to begin enrolment (on schedule)

Leadership Excellence

World leading clinicians & scientists:
A team to cure cancer

Jonathan Kwok

CEO & CO-FOUNDER

Lian Ni Lee

VP PRECLINICAL & CO-FOUNDER

Senthil Chinnakannan

VP VECTOR DESIGN & CO-FOUNDER

Paul Klenerman

HEAD OF SCIENTIFIC ADVISORY BOARD

Mark Middleton

SCIENTIFIC ADVISORY BOARD MEMBER

Teresa Lambe

SCIENTIFIC ADVISORY BOARD MEMBER

Catherine Green

SCIENTIFIC ADVISORY BOARD MEMBER
Blue small t-cellBlue big t-cellBlue small t-cell
CONTACT Us

Empower Change:
Investors, Industry Partners, and Visionaries wanted!

Explore investment opportunities, forge impactful partnerships, and embark on a rewarding career journey. Together, we can make a lasting difference in the fight against cancer.